07
Dec
SFA Therapeutics Announces Updated Psoriasis Data for SFA-002, Bridge Financing, and Foundational Patent
in News
Comments
SFA-002 Updated Extension Data Showing 92% PASI 50 and 72% PASI 75 $4.5 Million Bridge Financing led by North South Ventures Composition of Matter patent which covers over 40 potential disease indications for SFA-002 JENKINTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- SFA Therapeutics, a clinical-stage biotech using a first-in-class immuno-modulation technology platform, is pleased to announce the completion of a bridge financing of $4.5 million, led...
Read More
